Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00091312
First received: September 7, 2004
Last updated: February 6, 2009
Last verified: December 2006
  Purpose

RATIONALE: Drugs used in chemotherapy, such as irinotecan, leucovorin, and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known whether combination chemotherapy is more effective than observation alone in treating patients who have undergone surgery for colon cancer.

PURPOSE: This randomized phase III trial is studying irinotecan and fluorouracil with or without leucovorin to see how well they work compared to observation alone in treating patients who have undergone surgery for stage II colon cancer.


Condition Intervention Phase
Colorectal Cancer
Drug: FOLFIRI regimen
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Procedure: adjuvant therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Disease-free survival at 5 years [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival at 8 years [ Designated as safety issue: No ]
  • Tolerability [ Designated as safety issue: Yes ]
  • Correlation of clinical, histological, and biological prognostic factors with outcome [ Designated as safety issue: No ]

Estimated Enrollment: 1976
Study Start Date: June 2004
Detailed Description:

OBJECTIVES:

Primary

  • Compare 5-year disease-free survival in patients with resected stage II adenocarcinoma of the colon treated with adjuvant chemotherapy comprising fluorouracil and irinotecan with or without leucovorin calcium vs no adjuvant therapy.

Secondary

  • Compare 8-year overall survival in patients treated with these regimens.
  • Compare tolerability of these regimens in these patients.
  • Correlate clinical, histological, and biological prognostic factors with outcome in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, disease stage (pT3 vs pT4), pathological differentiation (poorly or undifferentiated vs well or moderately differentiated), and microsatellite instability (positive vs negative vs unknown). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients are further randomized to receive 1 of 3 adjuvant chemotherapy regimens.

    • Regimen A: Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1, 15, and 29. Treatment repeats every 42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
    • Regimen B: Patients receive irinotecan IV over 30-90 minutes followed by leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 24 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
    • Regimen C: Patients receive irinotecan IV over 60 minutes followed by fluorouracil IV continuously over 48 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients undergo observation only. Patients are followed every 6 months.

PROJECTED ACCRUAL: A total of 1,976 patients (988 per treatment arm [247 each in regimens A and B of arm I and 494 in regimen C of arm I]) will be accrued for this study within 4.5 years.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the colon

    • Stage II disease (pT3, N0 or pT4, N0)

      • Penetration of the subserosa or serosa
      • No lymph node metastases

        • At least 12 lymph nodes analyzed
  • More than 1 synchronous primary colon tumor allowed

    • Staging determined for the more advanced tumor
  • Curative radical resection within the past 2-8 weeks required

    • Proximal, distal, and radical margins must be free of tumor (R0 resection)
  • No rectal tumors

    • Gross distal margin of the primary tumor must lie above the peritoneal reflection
  • No known familial adenomatous polyposis
  • No hereditary nonpolyposis colorectal cancer
  • No distant metastases

PATIENT CHARACTERISTICS:

Age

  • 18 to 75

Performance status

  • WHO 0-1

Life expectancy

  • Not specified

Hematopoietic

  • Granulocyte count ≥ 2,000/mm^3
  • Platelet count ≥ 100,000mm^3
  • Hemoglobin ≥ 10 g/dL

Hepatic

  • Bilirubin < 1.25 times upper limit of normal (ULN)
  • No known Gilbert's syndrome

Renal

  • Creatinine < 1.25 times ULN

Cardiovascular

  • No severe or uncontrolled coronary disease
  • No severe heart failure
  • No uncontrolled arterial hypertension
  • No myocardial infarction within the past year
  • No cerebral vascular accident within the past year
  • Cardiac arrhythmia allowed provided patient is on proper anticoagulation therapy* NOTE: *Aspirin is not considered proper anticoagulation

Gastrointestinal

  • No Gardner's syndrome
  • No Turcot's syndrome
  • No Crohn's disease
  • No ulcerative colitis

Other

  • No other prior malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
  • No other serious disease
  • No contraindication to any study drugs
  • No known allergy to leucovorin calcium
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for up to 6 months after study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • No prior chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radiotherapy

Surgery

  • See Disease Characteristics

Other

  • No other concurrent anticancer therapy
  • No concurrent vitamin supplements containing folic acid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00091312

Locations
Egypt
National Cancer Institute - Cairo
Cairo, Egypt
France
Centre Hospitalier Universitaire Ambroise Pare - Boulogne
Boulogne Billancourt, France, F-92104
Hopital Du Bocage
Dijon, France, 21034
Germany
Medizinische Klinik I
Dresden, Germany, D-01307
Italy
Ospedali Riuniti di Bergamo
Bergamo, Italy, 24100
Azienda Ospedaliero Careggi
Florence, Italy, 50139
Universita Degli Studi di Florence - Policlinico di Careggi
Florence, Italy, 50139
Portugal
Instituto Portugues de Oncologia Centro do Porto, S. A.
Porto, Portugal, 4200-072
Spain
Hospital Universitario de Elche
Elche Alicante, Spain, E-03203
Sponsors and Collaborators
Federation Francophone de Cancerologie Digestive
Investigators
Study Chair: Laurent Bedenne, MD Hopital Du Bocage
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00091312     History of Changes
Other Study ID Numbers: CDR0000387797, FFCD-EORTC-40012, EORTC-40012, PETACC-4
Study First Received: September 7, 2004
Last Updated: February 6, 2009
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage II colon cancer
adenocarcinoma of the colon

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Irinotecan
Fluorouracil
Levoleucovorin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antidotes
Protective Agents

ClinicalTrials.gov processed this record on September 22, 2014